ArriVent BioPharma (AVBP) News Today $26.09 +0.44 (+1.72%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period ArriVent BioPharma, Inc. (NASDAQ:AVBP) Sees Significant Growth in Short InterestArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report) saw a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 3,310,000 shares, an increase of 6.1% from the November 15th total of 3,120,000 shares. Based on an average daily volume of 249,100 shares, the short-interest ratio is presently 13.3 days. Currently, 17.0% of the shares of the company are sold short.December 15, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Buys 122,641 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP)Charles Schwab Investment Management Inc. grew its stake in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) by 153.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 202,368 shares of theDecember 14, 2024 | marketbeat.comFmr LLC Boosts Stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP)Fmr LLC increased its holdings in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) by 8.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,119,695 shares of the company's stock after purchasinDecember 8, 2024 | marketbeat.comShort Interest in ArriVent BioPharma, Inc. (NASDAQ:AVBP) Decreases By 11.9%ArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report) was the target of a large decline in short interest during the month of November. As of November 15th, there was short interest totalling 3,120,000 shares, a decline of 11.9% from the October 31st total of 3,540,000 shares. Based on an average trading volume of 275,700 shares, the days-to-cover ratio is currently 11.3 days. Currently, 16.1% of the shares of the stock are short sold.December 1, 2024 | marketbeat.comSuvretta Capital Management LLC Buys 132,459 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP)Suvretta Capital Management LLC boosted its stake in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) by 7.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,845,162 shares of the comNovember 29, 2024 | marketbeat.comArriVent BioPharma Advances Cancer Therapeutics PipelineNovember 19, 2024 | markets.businessinsider.comArriVent BioPharma Reports Advancements and Q3 2024 Financial ResultsNovember 16, 2024 | msn.comArriVent BioPharma, Inc.: Promising Clinical Trials and Strategic Collaborations Drive Buy RatingNovember 16, 2024 | markets.businessinsider.comArriVent BioPharma, Inc. Buy Rating: Strong Financials, Clinical Progress, and Promising Catalysts Support Upside PotentialNovember 16, 2024 | markets.businessinsider.comArriVent BioPharma's (AVBP) Buy Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $36.00 price objective on shares of ArriVent BioPharma in a research note on Friday.November 15, 2024 | marketbeat.comArriVent BioPharma Reports Third Quarter 2024 Financial ResultsNovember 14, 2024 | markets.businessinsider.comDiscover the 3 Best-Performing Biotech IPO Stocks of 2024 (AVBP)Check out which three biotechnology companies that went public in 2024 and are performing the best and a big factor influenced their rise.November 6, 2024 | marketbeat.comAlphaCentric Advisors LLC Sells 71,000 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP)AlphaCentric Advisors LLC trimmed its position in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) by 82.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,000 shares of the company's stock after selliNovember 5, 2024 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Hits New 1-Year High - Should You Buy?ArriVent BioPharma (NASDAQ:AVBP) Hits New 52-Week High - Still a Buy?October 24, 2024 | marketbeat.comArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest UpdateArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report) was the recipient of a large growth in short interest in the month of September. As of September 30th, there was short interest totalling 3,350,000 shares, a growth of 80.1% from the September 15th total of 1,860,000 shares. Currently, 17.3% of the shares of the company are short sold. Based on an average daily trading volume, of 249,500 shares, the days-to-cover ratio is presently 13.4 days.October 12, 2024 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Shares Up 6.3%ArriVent BioPharma (NASDAQ:AVBP) Trading 6.3% HigherOctober 3, 2024 | marketbeat.comNovo Holdings A S Raises Stock Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP)Novo Holdings A S boosted its position in ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) by 39.3% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,500,000 shares of the company's stock after purchasing an additional 422,860September 30, 2024 | marketbeat.comShort Interest in ArriVent BioPharma, Inc. (NASDAQ:AVBP) Rises By 13.4%ArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report) was the target of a significant increase in short interest in September. As of September 15th, there was short interest totalling 1,860,000 shares, an increase of 13.4% from the August 31st total of 1,640,000 shares. Approximately 9.6% of the company's stock are sold short. Based on an average trading volume of 234,300 shares, the short-interest ratio is presently 7.9 days.September 29, 2024 | marketbeat.comBuy Rating for ArriVent BioPharma Backed by Firmonernib’s Efficacy in NSCLC TrialsSeptember 24, 2024 | markets.businessinsider.comBiocureTechInc (CURE-X.CN)September 20, 2024 | finance.yahoo.comArriVent BioPharma (NASDAQ:AVBP) Shares Gap Down to $23.94ArriVent BioPharma (NASDAQ:AVBP) Shares Gap Down to $23.94September 18, 2024 | marketbeat.comArriVent BioPharma: Bringing A Novel Cancer Drug From ChinaSeptember 18, 2024 | seekingalpha.comAnalyst boosts ArriVent BioPharma shares price target after promising trial dataSeptember 12, 2024 | uk.investing.comArriVent BioPharma stock target raised on positive trial resultsSeptember 12, 2024 | investing.comArriVent BioPharma (NASDAQ:AVBP) Shares Down 4.3% ArriVent BioPharma (NASDAQ:AVBP) Shares Down 4.3%September 11, 2024 | marketbeat.comArriVent BioPharma, Inc.: Strong Clinical Data and Improved Financial Outlook Prompt Buy Rating and Price Target IncreaseSeptember 11, 2024 | markets.businessinsider.comArriVent BioPharma (NASDAQ:AVBP) PT Raised to $36.00 at CitigroupCitigroup boosted their price target on ArriVent BioPharma from $30.00 to $36.00 and gave the company a "buy" rating in a research note on Wednesday.September 11, 2024 | marketbeat.comArriVent BioPharma Unveils Promising Phase 1b Data for Firmonertinib in Treating NSCLCSeptember 11, 2024 | msn.comBuy Rating Affirmed for ArriVent BioPharma on Firmonertinib’s Promising Study Results and Market PotentialSeptember 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for ArriVent BioPharma Amid Promising Firmonertinib Trial ResultsSeptember 11, 2024 | markets.businessinsider.comArriVent BioPharma (NASDAQ:AVBP) Receives Outperform Rating from OppenheimerOppenheimer reaffirmed an "outperform" rating and set a $39.00 price objective (up from $35.00) on shares of ArriVent BioPharma in a research note on Tuesday.September 10, 2024 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Shares Gap Up After Analyst UpgradeArriVent BioPharma (NASDAQ:AVBP) Shares Gap Up Following Analyst UpgradeSeptember 10, 2024 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $38.00 at The Goldman Sachs GroupThe Goldman Sachs Group upped their price target on ArriVent BioPharma from $28.00 to $38.00 and gave the stock a "buy" rating in a research note on Tuesday.September 10, 2024 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Sees Large Volume IncreaseArriVent BioPharma (NASDAQ:AVBP) Sees Strong Trading VolumeSeptember 9, 2024 | marketbeat.comArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung CancerSeptember 9, 2024 | globenewswire.comWe're Not Very Worried About ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn RateSeptember 6, 2024 | finance.yahoo.comArriVent BioPharma (NASDAQ:AVBP) Trading 3.2% Higher ArriVent BioPharma (NASDAQ:AVBP) Trading 3.2% HigherSeptember 6, 2024 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Trading Up 2.4%ArriVent BioPharma (NASDAQ:AVBP) Trading 2.4% HigherAugust 28, 2024 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Hits New 52-Week High at $26.24ArriVent BioPharma (NASDAQ:AVBP) Sets New 52-Week High at $26.24August 26, 2024 | marketbeat.comArriVent BioPharma’s Firmonertinib: A Promising Treatment for EGFR PACC Mutations in NSCLCAugust 26, 2024 | markets.businessinsider.comHere's What Could Help ArriVent BioPharma, Inc. (AVBP) Maintain Its Recent Price StrengthAugust 19, 2024 | msn.comBuy Rating Affirmed for ArriVent BioPharma on Strong Clinical Prospects and Financial StabilityAugust 16, 2024 | markets.businessinsider.comHC Wainwright Boosts ArriVent BioPharma (NASDAQ:AVBP) Price Target to $30.00HC Wainwright lifted their price target on shares of ArriVent BioPharma from $25.00 to $30.00 and gave the company a "buy" rating in a report on Friday.August 16, 2024 | marketbeat.comArriVent BioPharma Reports Strong Second Quarter and Highlights ProgressAugust 16, 2024 | msn.comBuy Rating Affirmed on ArriVent BioPharma’s Strong Clinical Developments and Strategic PartnershipsAugust 16, 2024 | markets.businessinsider.comArriVent BioPharma (NASDAQ:AVBP) Announces Earnings ResultsArriVent BioPharma (NASDAQ:AVBP - Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.65) EPS for the quarter, meeting analysts' consensus estimates of ($0.65).August 15, 2024 | marketbeat.comOppenheimer Reaffirms "Outperform" Rating for ArriVent BioPharma (NASDAQ:AVBP)Oppenheimer reissued an "outperform" rating and issued a $35.00 target price on shares of ArriVent BioPharma in a research note on Thursday.August 15, 2024 | marketbeat.comArriVent BioPharma, Inc.: ArriVent BioPharma Reports Second Quarter 2024 Financial ResultsAugust 15, 2024 | finanznachrichten.deAarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharmaAugust 15, 2024 | businesswire.comArriVent BioPharma Reports Second Quarter 2024 Financial ResultsAugust 14, 2024 | globenewswire.com Get ArriVent BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AVBP and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight. >> Register for the Workshop Now AVBP Media Mentions By Week AVBP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AVBP News Sentiment▼1.050.60▲Average Medical News Sentiment AVBP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AVBP Articles This Week▼12▲AVBP Articles Average Week Get ArriVent BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AVBP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Verona Pharma News Today Rhythm Pharmaceuticals News Today MoonLake Immunotherapeutics News Today Janux Therapeutics News Today Edgewise Therapeutics News Today Xenon Pharmaceuticals News Today Merus News Today ACADIA Pharmaceuticals News Today Twist Bioscience News Today MorphoSys News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AVBP) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArriVent BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ArriVent BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
